{"doi":"10.1089/mdr.2011.0163","title":"Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-Negative Pathogens in New York City","abstract":"<jats:p>\n                    Multidrug-resistant\n                    <jats:italic toggle=\"yes\">Acinetobacter baumannii</jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae,</jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Pseudomonas aeruginosa</jats:italic>\n                    have become common in many regions, often requiring therapy with colistin or polymyxin B. An increase in resistance to these agents would render many infections untreatable. We tested the activity of polymyxin B and the novel polymyxin analogue CB-182,804 against over 5,000 recent Gram-negative clinical isolates from New York City, a region with a high prevalence of multiresistant strains. Over 96% of\n                    <jats:italic toggle=\"yes\">Escherichia coli</jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">K. pneumoniae</jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">A. baumannii,</jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">P. aeruginosa</jats:italic>\n                    were susceptible to polymyxin B; only 76% of\n                    <jats:italic toggle=\"yes\">Enterobacter</jats:italic>\n                    spp. was susceptible. The MICs of CB-182,804 were generally two-fold higher than polymyxin B and cross-resistance was observed. The addition of rifampin resulted in synergistic inhibition and bactericidal activity in time kill studies, and restored activity against all polymyxin-resistant strains. The synergistic effect of the combination with rifampin was most pronounced against\n                    <jats:italic toggle=\"yes\">A. baumannii</jats:italic>\n                    strains, and was slightly greater with CB-182,804 than with polymyxin B against\n                    <jats:italic toggle=\"yes\">K. pneumoniae</jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Enterobacter</jats:italic>\n                    spp. Despite considerable usage of polymyxin B and colistin in this region, polymyxin B retains excellent activity against most Gram-negative isolates. CB-182,804 shows similar activity, particularly when combined with rifampin. The clinical utility of CB-182,804 remains to be determined.\n                  </jats:p>","journal":"Microbial Drug Resistance","year":2012,"id":676683,"datarank":1.8708703252137395,"base_score":3.6888794541139363,"endowment":3.6888794541139363,"self_citation_contribution":0.5533319181170905,"citation_network_contribution":1.3175384070966492,"self_endowment_contribution":0.5533319181170905,"citer_contribution":1.3175384070966492,"corpus_percentile":null,"corpus_rank":null,"citation_count":39,"citer_count":39,"citers_with_citation_signal":37,"citers_with_endowment":37,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":431025,"name":"Neha Shah","orcid":"0000-0002-9575-9161","position":1,"is_corresponding":false},{"id":292863,"name":"Paul Kelly","orcid":"0000-0003-0844-6448","position":2,"is_corresponding":false},{"id":1484128,"name":"Elizabeth Babu","orcid":"0000-0002-0305-0412","position":3,"is_corresponding":false},{"id":1768033,"name":"Martin Backer","orcid":null,"position":4,"is_corresponding":false},{"id":1768034,"name":"Gabriella Rosas-Garcia","orcid":null,"position":5,"is_corresponding":false},{"id":1768035,"name":"Julius Salamera","orcid":null,"position":6,"is_corresponding":false},{"id":1768036,"name":"Avrille George","orcid":null,"position":7,"is_corresponding":false},{"id":1768038,"name":"Simona Bratu","orcid":null,"position":8,"is_corresponding":false},{"id":1768040,"name":"David Landman","orcid":null,"position":9,"is_corresponding":false},{"id":1768030,"name":"John Quale","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-Negative Pathogens in New York City","abstract":"<jats:p>\n                    Multidrug-resistant\n                    <jats:italic toggle=\"yes\">Acinetobacter baumannii</jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae,</jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Pseudomonas aeruginosa</jats:italic>\n                    have become common in many regions, often requiring therapy with colistin or polymyxin B. An increase in resistance to these agents would render many infections untreatable. We tested the activity of polymyxin B and the novel polymyxin analogue CB-182,804 against over 5,000 recent Gram-negative clinical isolates from New York City, a region with a high prevalence of multiresistant strains. Over 96% of\n                    <jats:italic toggle=\"yes\">Escherichia coli</jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">K. pneumoniae</jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">A. baumannii,</jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">P. aeruginosa</jats:italic>\n                    were susceptible to polymyxin B; only 76% of\n                    <jats:italic toggle=\"yes\">Enterobacter</jats:italic>\n                    spp. was susceptible. The MICs of CB-182,804 were generally two-fold higher than polymyxin B and cross-resistance was observed. The addition of rifampin resulted in synergistic inhibition and bactericidal activity in time kill studies, and restored activity against all polymyxin-resistant strains. The synergistic effect of the combination with rifampin was most pronounced against\n                    <jats:italic toggle=\"yes\">A. baumannii</jats:italic>\n                    strains, and was slightly greater with CB-182,804 than with polymyxin B against\n                    <jats:italic toggle=\"yes\">K. pneumoniae</jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Enterobacter</jats:italic>\n                    spp. Despite considerable usage of polymyxin B and colistin in this region, polymyxin B retains excellent activity against most Gram-negative isolates. CB-182,804 shows similar activity, particularly when combined with rifampin. The clinical utility of CB-182,804 remains to be determined.\n                  </jats:p>","is_dataset_classified":null,"base_score":3.6888794541139363,"endowment":3.6888794541139363,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22196342","pmcid":null,"openalex_id":"https://openalex.org/W2038305694","authors":[],"funders":[],"total_grants":0,"fwci":1.4684,"citation_percentile":0.79286828,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":10},{"year":2014,"count":3},{"year":2015,"count":1},{"year":2016,"count":3},{"year":2017,"count":2},{"year":2018,"count":4},{"year":2019,"count":5},{"year":2020,"count":2},{"year":2021,"count":1},{"year":2022,"count":4},{"year":2023,"count":2},{"year":2024,"count":1}],"oa_status":"closed","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://journals.sagepub.com/doi/full-xml/10.1089/mdr.2011.0163","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/pdf/10.1089/mdr.2011.0163","host_type":"publisher"},{"url":"https://doi.org/10.1089/mdr.2011.0163","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22196342","host_type":"repository"}],"fields_of_study":["Antibiotic Resistance in Bacteria","Antibiotics Pharmacokinetics and Efficacy","Pneumocystis jirovecii pneumonia detection and treatment","Anti-Bacterial Agents","Drug Resistance, Multiple, Bacterial","Drug Synergism","Gram-Negative Bacteria","Gram-Negative Bacterial Infections","Humans","Microbial Sensitivity Tests","New York City","Polymyxin B","Polymyxins","Rifampin"],"mesh_terms":["Anti-Bacterial Agents","Drug Synergism","Gram-Negative Bacteria","Humans","Microbial Sensitivity Tests","New York City","Polymyxin B","Polymyxins","Rifampin","Gram-Negative Bacterial Infections","Drug Resistance, Multiple, Bacterial"],"keywords":["Polymyxin B","Polymyxin","Colistin","Acinetobacter baumannii","Microbiology","Pseudomonas aeruginosa","Klebsiella pneumoniae","Enterobacter","Biology","Antibiotics","Escherichia coli","Bacteria"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T02:58:00.438607Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}